Diffuse large B-cell lymphoma (DLBCL) can present as de novo or can arise through the transformation of many indolent lymphomas, including follicular lymphoma (FL). The morphological differentiation between germinal center-DLBCL (GC-DLBCL) and high-grade (grade 3) FL could be challenging; the accurate sub-classification of large B-cell lymphomas is mandatory in order to select the most appropriate among the new-targeted therapies. Recent expression profiling studies reported microRNAs (miRNAs) (and miR-17-92 cluster, in particular) as useful tools in differentiating DLBCL and FL. However, these preliminary results are based on cell line-derived data or did not consider grade 3 FL cases. To investigate this point, 36 cases of GC-DLBCL and 18 cases of grade 3 non-transforming FL were considered. All diagnoses were based on the World Health Organization criteria and were confirmed by clinical, histological, and immunohistochemical data. Six members of the miR-17-92 cluster (ie, miR-18b, miR-19b, miR-20a, miR-92, miR-93, and miR-106a) and two control miRNAs (ie, miR-150 and miR-210) were quantified by quantitative reverse transcription-polymerase chain reaction. All the considered miR-17-92 cluster miRNAs were significantly overexpressed in GC-DLBCL, being miR-20a and miR-106a the most dysregulated (Po0.001). Receiver operating characteristics (ROCs) analysis was used to find the optimal cut-off in distinguishing the two histotypes. The ROC estimated thresholds for miR-18b, miR-19b, miR-20a, miR-92, and miR-106a displayed a sensitivity level higher than 0.80 in achieving the GC-DLBCL diagnosis. The classification tree built on the six thresholds allowed the correct identification of 35/36 GC-DLBCL (97.2%). Profiling the miR-17-92 cluster is a promising investigative method for differentiating GC-DLBCL from high-grade FL. Subject to the validation of these findings in further larger studies; miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
targeting messenger RNAs and triggering either the repression of their translation or their degradation. 15 MiRNAs are involved in several biological pathways, including development, cell proliferation, differentiation, and apoptosis and have been considered as a promising new class of biomarkers for tumor diagnosis and prognosis. 16 Recently, several reports have investigated miRNAs expression profiling in differentiating GC-B-cell lymphomas (BCLs), focusing on DLBCL and high-grade FL in particular. [17] [18] [19] Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the miRNA profile of DLBCL. 20 Among others, several miRNAs of the miR-17-92 cluster have been demonstrated to be the most promising. [17] [18] [19] [20] The miR-17-92 cluster, located at chromosome locus 13q31.3, consists of six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a) and two paralogs (the miR-106b-25 cluster on chromosome 7 and the miR-106a-363 cluster on chromosome X). 21, 22 A large volume of experimental data demonstrated the oncogenic role of miR-17-92 cluster in both hematopoietic malignancies and solid tumors, being involved in the regulation of cell cycle and cell death. [23] [24] [25] [26] Despite the important role demonstrated for the miR-17-92 cluster, no study has previously assessed its diagnostic value in differentiating GC-DLBCL from high-grade (G3; non-transforming) FL. In the present work, we investigated a cohort of patients with large BCL, comparing the differences in miRNA expression.
MATERIALS AND METHODS Patients and Tissue Specimens
Tissue samples of 36 cases of de novo GC-DLBCL (ie, with no clinical history of indolent lymphoma, or coexisting FL areas at diagnosis) and 18 of high-grade (grade 3) non-transforming FL reported between 2005 and 2009 were retrieved from the archives of the Surgical Pathology and Cytopathology Unit of the University of Padua and included in the study (Table 1 ). In particular, to prevent intra-specimen variability, FL cases were selected considering only cases with diffuse areas proportion o25% (ie, FL follicular pattern; Figures 1a and b) and which were diffusely grade 3 (ie, grade 3: 475% of the neoplastic area). 27, 28 All diagnoses were based on the World Health Organization criteria and confirmed in all instances by two pathologists (FM and AF) by clinical, histological, and IHC data. 27, 28 Five lymph nodes with minor reactive changes, obtained by sleeve gastrectomies for the treatment of obesity, were included as non-neoplastic lymphatic tissue (N). The University Hospital of Padua institute's ethical regulations on research conducted on human tissues were followed.
Ethic Statement
Written informed consent was obtained from all participants involved in the study and the study was approved by the institutional review board of the University Hospital of Padua (Azienda Ospedaliera di Padova-Università degli Studi di Padova).
Immunohistochemistry
Immunohistochemistry was performed on 4-5 mm-thick formalin-fixed and paraffin-embedded (FFPE) sections from each tumor sample. Using the standard avidin-biotin-peroxidase complex method, staining was done automatically (BondmaX, Menarini, Florence, Italy), as described elsewhere, 29 7 Sections were then slightly counterstained with hematoxylin. Appropriate positive and negative controls were run concurrently. The expression of each IHC marker was jointly scored by three of the authors (FM, AF, and RC) and dichotomized as positive or negative.
B-Cell Clonality B-cell clonality was evaluated by the detection of Ig genes rearrangement, using the B-cell lymphoma kitt (Experteam, Venice, Italy). In all cases, 5 mm thick sections were obtained from FFPE tissues of each neoplastic/non-neoplastic sample. Genomic DNA was extracted from these sections previously digested with proteinase K. Ig chain gene clonality was evaluated according to the manufacturer's instructions.
MiRNA Selection
Recent expression profiling studies identified members of the miR-17-92 cluster (ie, miR-19b, miR-20a, and miR-92) and three of its paralogs (ie, miR18b, miR-93, and miR-106a) as useful biomarkers in differentiating DLBCL from low-grade FL. [17] [18] [19] Consequently, the diagnostic performance of these miRNAs was explored in our series of GC-DLBCL and highgrade (grade 3) non-transforming FL. To further support the qRT-PCR data, both miR-150 and miR-210 were selected as controls: (i) miR-150 has been reported to be a key regulator of normal hematopoiesis targeting MYB, being downregulated in lymphoid neoplasm; 31 (ii) miR-210 has been demonstrated to be an oncomiR involved in the cell cycle and considered to be overexpressed in many tumors, as well as lymphomas. 32 
RNA Extraction
Using a sterile Harris Micro-Puncht (Sigma-Aldrich, St Louis, MO, USA), 2-mm tissue cores were obtained from the paraffin block of each tumor/normal sample. Total RNA was extracted using the RecoverAll kit (Ambion, Austin, TX, USA), as reported elsewhere. 33 The sample was then grinded on dry ice, placed in a 1.5 ml microcentrifuge tube containing 1 ml of xylene, vortexed and incubated at 50 1C for 3 min to melt the paraffin. The material was then centrifuged at 14 000 r.p.m. for 10 min at room temperature to pellet the specimen, after which the xylene was carefully removed and the pellet was washed three times with 1 ml of 100% room temperature ethanol. The pellet was then air-dried at room temperature for 45 min. Following deparaffinization, tissue was protease digested by incubating the pellet in 200 ml digestion buffer and 4 ml protease at 80 1C for 15 min. For total RNA isolation, 240 ml of isolation additive was added to the sample, followed by vortexing and addition of 550 ml of 100% ethanol. The mixture was then loaded onto a prepared filter and collection tube according to the manufacturersupplied procedure. The sample was centrifuged for 30 s at 10 000 r.p.m. Flow through was discarded and filter washed miRNAs and large B-cell lymphomas A Fassina et al twice with wash buffer. Nuclease digestion was obtained by adding 60 ml DNase master mix (containing 6 ml 10 Â DNase buffer, 4 ml DNase, 50 ml nuclease-free water) to the center of the filter and incubated for 30 min at room temperature. The filter was subsequently washed three times according to the manufacturer's protocol, and RNA was eluted with 60 ml preheated nuclease-free water. RNA quality and quantity was measured by Nanodrop technology (Thermo Scientific, Wilmington, DE, USA). The eluted RNAs were immediately aliquoted (into 20 ml volumes) and stored at À 80 1C until all extractions were completed. To avoid any potential variation between assays, analyses were carried out on all of the extracts simultaneously.
Reverse Transcription and Quantitative Real-Time PCR To detect and quantify mature miRNAs, the NCode TM miRNA quantitative real-time PCR (qRT-PCR) method (Invitrogen, Carlsbad, CA, USA) was applied according to the manufacturer's instructions. Reverse transcription (RT) and poly(A) tailing reactions were performed with 4 ml 5 Â reaction mix, 2 ml 10 Â SuperScript enzyme mix, and 500 ng of total RNA in a final volume of 20 ml. The mixture was incubated at 37 1C for 60 min. Following RT steps, qRT-PCR was performed: 2 ml of the RT product was transferred into a PCR reaction mixture consisting of 10 ml Express SYBR green qPCR SuperMix with premixed ROX, 0.4 ml miRNA-specific forward primer (10 mM; primers sequence in Table 2 ), 0.4 ml universal qPCR primer (10 mM) in a final volume of 20 ml. Statistical Analysis Differential expression was tested for all single miRNA species using two-sided t-test, after checking both the assumption of normality (Shapiro-Wilk's test) and the assumption of homogeneity of variance (F-test). Receiver operating characteristics (ROCs) analysis was used to find out the optimal cut-offs for miRNAs' expression for stratifying cases according to their final histopatological diagnosis (GC-DLBCL vs high-grade FL). A classification tree was trained on a prefiltered set of miRNA profiles. MiRNAs were considered only if they were significantly differentiated among GC-DLBCL and high-grade FL. The classification tree was calculated using the Euclidean distance. A P-valueo0.05 was considered statistically significant. All statistical analyses were performed using the R software (R Development Core Team, version 2.9; R Foundation for Statistical Computing, Vienna, Austria; www.R-project.org).
RESULTS

Clinical-Pathological Characteristics of the Patients' Series
Overall, the male/female ratio was 13/23 for GC-DLBCL and 12/6 for high-grade FL; patients mean age was 65. Figure 1e) , and all the tumors lacked an expression of either CD5 or Cyclin D1. In FL, follicular dendritic cells (FDC) are important to the microenviroment in which FL cells grow, as a result we performed IHC analysis with monoclonal antibodies for CD21 and CD23, markers of FDC. 34 Both antibodies (CD21 mostly negative in the neoplastic counterpart, whereas CD23 was variably positive also in FL neoplastic cells) irregularly highlighted, in FL cases, the remnants of the FDC network, Figure 2 ; Table 3 ), being miR-20a and miR-106a the most dysregulated (Po0.001; Figure 2 ; Table 3 ). The expression levels of miR-150 and miR-210 were similar in the GC-DLBCL and grade 3 FL groups ( Figure 2 ; Table 3 ). Notably, GC-DLBCL also showed significantly higher levels of the six miR-17-92 cluster miRNAs than N (all Po0.05; Figure 2 ; Table 3 ). Only miR-18b was significantly overexpressed in high-grade FL in comparison with N (P ¼ 0.001; Figure 2 ; Table 3 ), whereas the other five miR-17-92 cluster miRNAs showed a trend in overexpression in comparison with N ( Table 3) .
As expected, in both GC-DLBCL and high-grade FL, miR-210 showed higher expression levels in lymphomas than in N (both Po0.001; Figure 2 ; Table 3 ); conversely, miR-150 Figure 2 miR-17-92 microRNAs (miRNAs) cluster is differently expressed among germinal center (GC) large B-cell lymphomas. Box plots show difference in miRNAs expression between GC-diffuse large B-cell lymphomas (DLBCL), non-transforming follicular cell lymphomas (grade 3; FL), and non-tumor lymph-nodes (N). The six miR-17-92 cluster miRNAs were significantly overexpressed between DLBCL and grade 3 FL (all Po0.05), being miR-20a and miR-106a the most dysregulated (Po0.001). The expression levels of miR-150 and miR-210 were similar in these two groups. X axis: the three different histological groups considered in the analysis (DLBCL, FL, and N); Y axis: miRNAs relative expression levels (logarithmic scale). *Po0.05; **Po0.001.
miRNAs and large B-cell lymphomas A Fassina et al was downregulated in tumor samples in comparison with N (both Po0.001; Figure 2 ; Table 3 ).
No significant difference in miRNAs expression was observed among the 11 grade 3a and the 7 grade 3b FL cases and according to other clinicopathological characteristics (ie, Ann Arbor stage, age, and sex).
MiR-17-92 Cluster Differentiate Between GC-DLBCL and High-Grade FL ROC curves of miR-17-92 miRNA cluster expression were calculated to determine threshold, sensitivity, and specificity in distinguishing GC-DLBCL from high-grade FL. All these miRNAs were suitable to discriminate between the two groups, with a P-value o0.05 ( Table 4) .
The thresholds estimated for miR-18b, miR-19b, miR-20a, and miR-106a displayed sensitivity40.80 in confirming a GC-DLBCL diagnosis (Figure 3a ; Table 4 ). Conversely, only miR-92a and miR-93 thresholds demonstrated specificity 40.80 (0.89 and 0.83, respectively; Figure 3a ; Table 4 ).
The classification tree built on miR-17-92 miRNA cluster expression profiles displayed that altogether the obtained 
DISCUSSION
DLBCL is a heterogeneous group of lymphomas consisting of large size solid sheets of transformed B cells, mainly resembling normal immunoblasts or centroblasts, with a partial/complete effacement of lymph node architecture. 27, 28 Immunoblasts are large cells with single prominent nucleolus and abundant cytoplasm often with plasmocytoid appearance. Centroblasts present as large, non-cleaved cells with round/ oval nuclei, multiple nucleoli, vesicular chromatin, and basophilic cytoplasm. 27, 28 These last cellular features may overlap those of grade 3 FL, in which the proportion of centrocytes (small/medium sized cells with cleaved nuclei, inconspicuous nucleoli, and scant cytoplasm) and centroblasts varies up to the complete absence of centrocytes. 27, 28 Moreover, in the presence of diffuse areas (425%) of blastic cells in a grade 3 FL, the cases have been proposed to be referred as a full-blown DLBCL. 27, 28, 35 Also by the molecular point of view, DLBCL includes genetic and molecular alterations often shared with high-grade FL. Both these lymphomas generally express B-cell antigens (CD-19, CD-20, and CD-79a), surface/cytoplasmic immunoglobulin, and (in various proportions) CD10, BCL-2 protein, and BCL-6 protein. 16, [36] [37] [38] DLBCL may also share with high-grade FL the t(14;18) translocation, which results with an overexpression of the BCL-2 oncogene, [39] [40] [41] [42] and abnormalities involving the BCL-6 gene, which encodes an essential transcription factor for the GC development. 43, 44 Thus, the morphological/molecular differentiation between DLBCL (GC subtype in particular) and grade 3 FL could be challenging.
By the clinical point of view, grade 3 FL are mostly treated as an aggressive disease, as DLBCL. 8 More recently, some authors are proposing to consider the 3a group as an indolent BCL and the 3b as clinically similar to DLBCL, but conflicting data have been published. 8 In fact, in contrast to DLBCL, the relapse rate of grade 3b FL is in some series higher and survival is longer. 9, 10, 45 Moreover, several reports have found no difference in outcome between FL grades 3a and 3b when treated with anthracycline-based therapy, and molecular studies identified comparable gene expression profiles between FL grade 3a and FL grade 3b. [11] [12] [13] [14] These findings, the advent of new-targeted therapies, and the clinical followup with limited sampling of the disease (ie, peripheral blood, fine needle aspiration biopsies) strictly demand new diagnostic tools able to differentiate such similar diseases.
Recent reports have demonstrated the diagnostic impact of miRNAs in human pathology. 15, 46 Owing to their structural characteristics, miRNAs are, in contrast to most mRNAs, very stable in vitro and long-lived in vivo, which might be critical in a clinical setting and allow analysis of samples obtained from different sources (ie, urine, blood, FFPE tissues). 16 Some recent articles investigated the diagnostic feasibility of miRNAs in discerning among large BCLs, and have established specific miRNA signatures able to differentiate these tumors. [17] [18] [19] Among the others, some authors investigated the different miRNA profiles between DLBCL and FL. However, these preliminary results are based on cell line-derived data or considering grade 1 and 2 FL (and not grade 3), affecting a comprehensive comparison among studies. [17] [18] [19] Thus, the aim of this study was to differentiate two morphologically and molecular similar nosological entities as GC-DLBCL and high-grade (G3) FL, using miRNA expression analysis, in the search of additional diagnostic tools to be used in daily pathology routine. 47 Seminal works highlighted the components of the miR-17-92 cluster, as some of the most dysregulated miRNAs in both DLBCL and FL. [17] [18] [19] Moreover, this cluster owns a recognized oncogenic potential in lymphoid malignancies. 22, 48 He et al 48 demonstrated that lentiviral transduction of the miR-17-92 cluster into hematopoietic cells dramatically accelerates lymphomagenesis in MYC transgenic mice. Of interest, the MYC oncogene has been recently shown to upregulate the expression of the miR-17-92 cluster and emerged as a key regulator of the miRNA profile in DLBCL. 20 In humans, chromosomal amplification at 13q31-q32 leads to the cluster's miRNAs overexpression (the chromosome 13 open reading frame 25 gene; C13orf25) in several BCLs, including DLBCL and high-grade FL. [48] [49] [50] The biological importance of the miR-17-92 cluster is further underlined by the presence of its paralogs on chromosomes 7 and X: these miRNAs, located in different chromosomes, derive from a unique gene that underwent a series of dysregulations (duplications, mutations, and loss) during the early evolution of vertebrates. 22 Interestingly, the miRNAs in the cluster do not vary entirely in parallel with each other in B-cell lines, suggesting that either the processing or the stability of these miRNAs are differently regulated, and supporting the fact that only some of the cluster's components have been detected as dysregulated in large BCLs. 51 Thus, we decided to test miR-17-92 cluster feasibility as a useful diagnostic tool in differentiating DLBCL and highgrade FL. In our series, as expected, we observed a consistent overexpression of all the six miR-17-92 miRNAs tested in DLBCL and FL in comparison with the control lymphoid tissue. 48 The lack of statistical significance for five out of six miRNAs in the FL group should be related to the relatively small number of control tissue samples. However, the six miRNAs signature significantly discriminate the two different histopathological categories, and the classification tree built on the obtained ROC curves allowed a correct identification of the 97% of GC-DLBCL cases. Among the others, miR-20a and miR-106a showed the most significant differences in expression levels between DLBCL and FL cases, supporting the notion that the different miR-17-92 cluster elements are not concurrently dysregulated. 51 miRNAs and large B-cell lymphomas A Fassina et al Overexpression of miR-17-92 cluster members in GC-DLBCL in comparison with high-grade FL, further supports the oncogenic potential of these miRNAs. In fact, DLBCL could represent a more de-differentiated form in FL natural history. Lawrie et al 17 described among de novo and transformed DLBCL cases a FL transformed-specific miRNAs signature, which was characterized by the dysregulation of four of the members of the miR-17-92 cluster. In the Lawrie's study, miR-17-92 miRNAs expression levels were comparable between FL cases that subsequently underwent DLBCL transformation and those that did not, suggesting a late involvement of the miR-17-92 cluster only in the acquisition of a more biologically aggressive phenotype. 17 Further larger prospective studies are needed to confirm these data, and to investigate the possible role of miR-17-92 in FL transformation in GC-DLBCL, focusing not only on miR-17-92 diagnostic value, but also on its prognostic potentials.
The present results further show that miRNA profiling may be helpful in differentiating large BCLs. The identification of histotype-specific miRNA signature offers an exciting new insight into the molecular mechanism underlying lymphomagenesis and it may represent a novel reliable and standardizable diagnostic tool in the characterization of similar diseases, also in the presence of scant material obtained from mini-invasive procedures.
